Please note: This item is shipped directly from the manufacturer. Delivery may take slightly longer than usual, with an estimated turnaround time of 5 to 7 working days.
Novo-Lela Semaglutide 4mg Auto-Injector Pen contains Semaglutide, a GLP-1 receptor agonist approved for the treatment of type 2 diabetes. Semaglutide replicates the action of human glucagon-like peptide-1, enhancing glucose-dependent insulin secretion and suppressing glucagon release to regulate blood sugar levels effectively.
As a next-generation incretin therapy, Semaglutide has shown significant efficacy in reducing HbA1c levels and promoting weight loss. Clinical studies consistently demonstrate that Semaglutide provides superior glycaemic control compared to placebo and many other GLP-1 receptor agonists. Its additional effects on delaying gastric emptying further improve postprandial glucose control and contribute to reduced appetite and caloric intake.
The Auto-Injector Pen format offers a convenient, prefilled option for once-weekly subcutaneous administration, making treatment simple and discreet.
Benefits of Semaglutide:
-
Blood Sugar Regulation: Stimulates insulin secretion in response to high glucose and suppresses glucagon production, supporting stable blood sugar control.
-
Weight Loss Support: Reduces appetite and slows gastric emptying, assisting with sustained weight reduction.
-
Cardiovascular Protection: Evidence suggests a reduction in the risk of major adverse cardiovascular events in patients with type 2 diabetes.
Dosage Instructions:
Novo-Lela Semaglutide Auto-Injector Pen is designed for subcutaneous injection, providing a pre-measured dose.
General guidelines are as follows:
-
Type 2 Diabetes: Start with 0.25 mg once weekly for the first four weeks, then increase to 0.5 mg once weekly. The dose may be escalated to 1.0 mg if additional glycaemic control is needed.
-
Weight Management: Higher maintenance doses (up to 2.4 mg weekly) may be used based on clinical judgment and patient response.
-
Administer the injection on the same day each week, at any time, with or without food.
Always follow your healthcare provider’s instructions to ensure the correct dose and frequency are used.
Side Effects:
Semaglutide may cause certain side effects, although many are mild and improve with time:
-
Gastrointestinal Symptoms: Nausea, vomiting, diarrhea, or abdominal discomfort during dose escalation.
-
Hypoglycemia: Uncommon when used alone but can occur if combined with other blood sugar-lowering medications.
-
Injection Site Reactions: Mild redness, itching, or discomfort may occur.
-
Pancreatitis: Rare cases of pancreatic inflammation have been reported.
-
Gallbladder Effects: Long-term use may increase the risk of gallbladder-related events.
Patients should consult their healthcare provider regarding monitoring and management of potential side effects.
Half-life:
Semaglutide has a half-life of about one week, allowing for once-weekly injections. This extended activity ensures consistent glucose control and facilitates weight management without daily dosing.
In summary, Novo-Lela Semaglutide 4mg Auto-Injector Pen offers the same therapeutic benefits as traditional delivery methods, with the added convenience of a prefilled pen. It is a clinically effective GLP-1 receptor agonist that supports blood sugar control, weight loss, and cardiovascular health as part of a comprehensive treatment plan.